Effect of viral load and drug resistance on mortality among Chinese HIV-infected patients receiving Antiretroviral Treatment

Journal of Antivirals and Antiretrovirals

Volumn 4, Issue 3, 2012, Pages 060-065

  Wang, Xia ^a   Xing, Hui ^a   Ruan, Yuhua ^a   Liao, Lingjie ^a   Zhou, Haiwei ^a   Chen, Bin ^a   Su, Junqi ^a   Zheng, Wei ^a   Shao, Yiming ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

China; Combination antiretroviral therapy; HIV drug resistance; Mortality

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CD4+ T LYMPHOCYTE; CHINESE; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; RISK FACTOR; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 84867721268     PISSN: None     EISSN: 19485964     Source Type: Journal    
DOI: 10.4172/jaa.1000047     Document Type: Article

References (38)

1. 2008 Report on the global AIDS epidemic. UNAIDS.
2. Zhang F, Dou Z, Ma Y, Zhao Y, Liu Z, et al. (2009) Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med 151: 241-251, W-252.
3. Zhang F, Dou Z, Yu L, Xu J, Jiao JH, et al. (2008) The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis 47: 825-833.
4. Zhang F, Dou Z, Ma Y, Zhang Y, Zhao Y, et al. (2011) Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis 11: 516-524.
5. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, et al. (2009) The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 23: 1127-1134.
6. Johannessen A, Naman E, Kivuyo SL, Kasubi MJ, Holberg-Petersen M, et al. (2009) Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis 9: 108.
7. Koyalta D, Charpentier C, Beassamda J, Rey E, Si-Mohamed A, et al. (2009) High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. Clin Infect Dis 49: 155-159.
8. Wang X, Yang L, Li H, Zuo L, Liang S, et al. (2011) Factors associated with HIV virologic failure among patients on HAART for one year at three sentinel surveillance sites in China. Curr HIV Res 9: 103-111.
9. Liao L, Xing H, Shang H, Li J, Zhong P, et al. (2010) The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China. J Acquir Immune Defic Syndr 53: S10-S14.
10. Ruan Y, Xing H, Wang X, Tang H, Wang Z, et al. (2010) Virologic outcomes of first-line HAART and associated factors among Chinese patients with HIV in three sentinel antiretroviral treatment sites. Trop Med Int Health 15: 1357-1363.
11. Zhao Y, Poundstone KE, Montaner J, Wu ZY (2012) New policies and strategies to tackle HIV/AIDS in China. Chin Med J (Engl) 125: 1331-1337.
12. Ma Y, Zhao D, Yu L, Bulterys M, Robinson ML, et al. (2010) Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clin Infect Dis 50: 264-271.
13. Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L, et al. (2008) Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. AIDS 22: 2187-2198.
14. Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, et al. (2006) Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 3: e356.
15. Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, et al. (2009) Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis 49: 1582-1590.
16. Zhong P, Pan Q, Ning Z, Xue Y, Gong J, et al. (2007) Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai. AIDS Res Hum Retroviruses 23: 847-856.
17. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents:recommendations for a public health approach (2006 revision).
18. Xu JQ, Wang JJ, Han LF, Xu C, Ruan YH, et al. (2006) Epidemiology, clinical and laboratory characteristics of currently alive HIV-1 infected former blood donors naive to antiretroviral therapy in Anhui Province, China. Chin Med J (Engl) 119: 1941-1948.
19. Qian HZ, Vermund SH, Kaslow RA, Coffey CS, Chamot E, et al. (2006) Co-infection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China. AIDS 20: 1429-1435.
20. Fairall LR, Bachmann MO, Louwagie GM, van Vuuren C, Chikobvu P, et al. (2008) Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med 168: 86-93.
21. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817-824.
22. Egger M, May M, Chene G, Phillips AN, Ledergerber B, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360: 119-129.
23. Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F, et al. (2005) Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 19: 1081-1089.
24. Recsky MA, Brumme ZL, Chan KJ, Wynhoven B, Yip B, et al. (2004) Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy. J Infect Dis 190: 285-292.
25. Lucas GM, Gallant JE, Moore RD (2004) Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing. AIDS 18: 1539-1548.
26. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, et al. (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126: 946-954.
27. Kantor R, Shafer RW, Follansbee S, Taylor J, Shilane D, et al. (2004) Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 18: 1503-1511.
28. Abgrall S, Duval X, Joly V, Descamps D, Matheron S, et al. (2003) Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy. Clin Infect Dis 37: 1517-1526.
29. Bangsberg DR, Moss AR, Deeks SG (2004) Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 53: 696-699.
30. Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, et al. (2004) Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 189: 51-60.
31. Katlama C, Dominguez S, Gourlain K, Duvivier C, Delaugerre C, et al. (2004) Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 18: 217-226.
32. Murray M, Hogg RS, Lima VD, May MT, Moore DM, et al. (2012) The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Med 13: 89-97.
33. Degenhardt L, Hall W, Warner-Smith M (2006) Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex Transm Infect 3: 56-63.
34. Kapadia F, Cook JA, Cohen MH, Sohler N, Kovacs A, et al. (2005) The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use. Addiction 100: 990-1002.
35. Press N, Tyndall MW, Wood E, Hogg RS, Montaner JS (2002) Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 3: S112-S117.
36. Maier I, Wu GY (2002) Hepatitis C and HIV co-infection: a review. World J Gastroenterol 8: 577-579.
37. Backus LI, Phillips BR, Boothroyd DB, Mole LA, Burgess J, et al. (2005) Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 39: 613-619.
38. Palepu A, Tyndall M, Yip B, O'Shaughnessy MV, Hogg RS, et al. (2003) Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr 32: 522-526.